The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
A Direct Effect of Hyperinsulinemia on Serum Sex Hormone-Binding Globulin Levels in Obese Women with the Polycystic Ovary Syndrome*
Abstract
To determine whether hyperinsulinemia can directly reduce serum sex hormone-binding globulin (SHBG) levels in obese women with the polycystic ovary syndrome, six obese women with this disorder were studied. Before study, ovarian steroid production was suppressed in each woman by the administration of 7.5 mg of a long-acting GnRH agonist, leuprolide depot, im, on days -56, -28, and 0. This resulted in substantial reductions in serum concentrations of testosterone (from 1.72 +/- 0.29 nmol/L on day -56 to 0.32 +/- 0.09 nmol/L on day 0), non-SHBG-bound testosterone (from 104 +/- 16 pmol/L on day -56 to 19 +/- 5 pmol/L on day 0), androstenedione (from 7.25 +/- 1.65 nmol/L on day -56 to 2.78 +/- 0.94 nmol/L on day 0), estrone (from 371 +/- 71 pmol/L on day -56 to 156 +/- 29 pmol/L on day 0), estradiol (from 235 +/- 26 pmol/L on day -56 to 90 +/- 24 pmol/L on day 0), and progesterone (from 0.28 +/- 0.12 nmol/L on day -56 to 0.08 +/- 0.02 nmol/L on day 0). Serum SHBG levels, however, did not change (18.8 +/- 2.8 nmol/L on day -56 vs. 17.8 +/- 2.6 nmol/L on day 0). While continuing leuprolide treatment, the women were administered oral diazoxide (300 mg/day) for 10 days to suppress serum insulin levels. Diazoxide treatment resulted in suppressed insulin release during a 100-g oral glucose tolerance test (insulin area under the curve, 262 +/- 55 nmol/min.L on day 0 vs. 102 +/- 33 nmol/min.L on day 10; P less than 0.05) and deterioration of glucose tolerance. Serum testosterone, androstenedione, estrone, estradiol, and progesterone levels did not change during combined diazoxide and leuprolide treatment. In contrast, serum SHBG levels rose by 32% from 17.8 +/- 2.6 nmol/L on day 0 to 23.5 +/- 2.0 nmol/L on day 10 (P less than 0.003). Due primarily to the rise in serum SHBG levels, serum non-SHBG-bound testosterone levels fell by 43% from 19 +/- 5 pmol/L on day 0 to 11 +/- 4 pmol/L on day 10 (P = 0.05). These observations suggest that hyperinsulinemia directly reduces serum SHBG levels in obese women with the polycystic ovary syndrome independently of any effect on serum sex steroids.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hyperinsulinaemia also plays an indirect role in hyperandrogenism by inhibiting hepatic sex hormone-binding globulin (SHBG) production, thus increasing free testosterone (Kiddy et al., 1989;Nestler et al., 1991).”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Nestler et al., 1991
In the citing paper
“The result of IR is hyperinsulinemia, which has a central role in the pathogenesis of androgen excess in PCOS.”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [6]
Citations
Cites
Morgan, C. R., & Lazarow, A. (1963) · Diabetes · doi:10.2337/diab.12.2.115 · Cited by 2,197
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Correlation of Hyperandrogenism with Hyperinsulinism in Polycystic Ovarian Disease*
Burghen, G. A., Givens, J. R., & Kitabchi, A. E. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-50-1-113 · Cited by 919
Insulin resistance in nonobese patients with polycystic ovarian disease
CHANG, R. J., NAKAMURA, R. M., JUDD, H. L., & KAPLAN, S. A. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-356 · Cited by 704
REVIEW ARTICLE: THE POLYCYSTIC OVARY SYNDROME
Yen, S. S. C. (1980) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1980.tb02132.x · Cited by 697
PLYMATE, S. R., MATEJ, L. A., JONES, R. E., & FRIEDL, K. E. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-460 · Cited by 693
Self-citationBarbieri, R. L., Makris, A., Randall, R. W., Daniels, G. H., Kistner, R. W., & Ryan, K. J. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-5-904 · Cited by 629
NESTLER, J. E., BARLASCINI, C. O., CLORE, J. N., & BLACKARD, W. G. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-66-1-57 · Cited by 414
Self-citationKIDDY, D. S., SHARP, P. S., WHITE, D. M., SCANLON, M. F., MASON, H. D., BRAY, C. S., POLSON, D. W., REED, M. J., & FRANKS, S. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb00857.x · Cited by 364
Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease
DeVane, G. W., Czekala, N. M., Judd, H. L., & Yen, S. S. C. (1975) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(75)90081-2 · Cited by 338
Cited by
Sorted by citations
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Rosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603
Metadata
- Authors
- NESTLER, J. E., POWERS, L. P., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., RITTMASTER, R. S., CLORE, J. N., & BLACKARD, W. G.
- Affiliations
- Madigan Army Medical Center (US)
- ORCID
- PLYMATE, STEPHEN R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1991-01
- Volume
- 72
- Issue
- 1
- Pages
- 83-89
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2008509267
- Cited by
- 815
- References
- 38
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 25 · 2023: 25 · 2022: 28 · 2021: 38 · 2020: 27 · 2019: 25 · 2018: 18 · 2017: 25 · 2016: 25 · 2015: 30 · 2014: 22 · 2013: 27 · 2012: 18
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-18904)
- National Center for Research Resources (RR 00065, M01RR000065)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hyperinsulinemia, sex hormone-binding globulin, polycystic ovary syndrome, obesity, insulin resistance, diazoxide, leuprolide, GnRH agonist, testosterone, androstenedione, estradiol, estrone, glucose tolerance, insulin secretion, ovarian steroidogenesis, glucose-insulin interaction, insulin sensitivity index, insulin resistance index
- MeSH terms
- Adult, Androstenedione, Diazoxide, Estradiol, Estrone, Female, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Gonadotropin-Releasing Hormone, Obesity, Polycystic Ovary Syndrome, Progesterone, Sex Hormone-Binding Globulin, Testosterone, Androstane-3,17-diol, Leuprolide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review